You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBosentan
Accession NumberDB00559  (APRD00829)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Bosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer®. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.

Structure
Thumb
Synonyms
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
bosentán
bosentan
bosentanum
p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-bosentantablet125 mgoralAccel Pharma IncNot applicableNot applicableCanada
Act Bosentantablet125 mgoralActavis Pharma Company2012-06-05Not applicableCanada
Act Bosentantablet62.5 mgoralActavis Pharma Company2012-06-05Not applicableCanada
Bosentan Tabletstablet125 mgoralAccord Healthcare Inc2014-11-132015-06-02Canada
Ipg-bosentantablet62.5 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-bosentantablet125 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Mar-bosentantablet125 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-bosentantablet62.5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-bosentantablet62.5 mgoralMylan Pharmaceuticals Ulc2012-05-29Not applicableCanada
Mylan-bosentantablet125.0 mgoralMylan Pharmaceuticals Ulc2012-05-29Not applicableCanada
PMS-bosentantablet125 mgoralPharmascience Inc2012-06-12Not applicableCanada
PMS-bosentantablet62.5 mgoralPharmascience Inc2012-06-12Not applicableCanada
Sandoz Bosentantablet125 mgoralSandoz Canada Incorporated2012-06-13Not applicableCanada
Sandoz Bosentantablet62.5 mgoralSandoz Canada Incorporated2012-06-13Not applicableCanada
Teva-bosentantablet125.0 mgoralTeva Canada Limited2012-12-28Not applicableCanada
Teva-bosentantablet62.5 mgoralTeva Canada Limited2012-12-12Not applicableCanada
Tracleertablet, film coated62.5 mg/1oralActelion Pharmaceuticals US, Inc.2001-11-20Not applicableUs
Tracleertablet125 mgoralActelion Pharmaceuticals Ltd2001-12-14Not applicableCanada
Tracleertablet62.5 mgoralActelion Pharmaceuticals Ltd2001-12-14Not applicableCanada
Tracleertablet, film coated125 mg/1oralActelion Pharmaceuticals US, Inc.2001-11-20Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-bosentantablet62.5 mgoralApotex IncNot applicableNot applicableCanada
Apo-bosentantablet125.0 mgoralApotex IncNot applicableNot applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Bosentan monohydrate
157212-55-0
Thumb
  • InChI Key: SXTRWVVIEPWAKM-UHFFFAOYSA-N
  • Monoisotopic Mass: 569.194419532
  • Average Mass: 569.63
DBSALT001842
Categories
UNIIXUL93R30K2
CAS number147536-97-8
WeightAverage: 551.614
Monoisotopic: 551.183854375
Chemical FormulaC27H29N5O6S
InChI KeyInChIKey=GJPICJJJRGTNOD-UHFFFAOYSA-N
InChI
InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)
IUPAC Name
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide
SMILES
COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bipyrimidines and oligopyrimidines. These are organic compounds containing two or more pyrimidine rings directly linked to each other. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBipyrimidines and oligopyrimidines
Alternative Parents
Substituents
  • Bipyrimidine
  • Diaryl ether
  • Benzenesulfonamide
  • Phenylpropane
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Ether
  • Hydrocarbon derivative
  • Primary alcohol
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).
PharmacodynamicsBosentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Bosentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.
Mechanism of actionEndothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease. Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB. Bosentan has a slightly higher affinity for ETA receptors than for ETB receptors.
Related Articles
AbsorptionAbsolute bioavailability is approximately 50% and food does not affect absorption.
Volume of distribution
  • 18 L
Protein bindingGreater than 98% to plasma proteins, mainly albumin.
Metabolism

Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one of which, Ro 48-5033, is pharmacologically active and may contribute 10 to 20% to the total activity of the parent compound.

SubstrateEnzymesProduct
Bosentan
Bosentan metabolite Ro 48-5033Details
Bosentan
Bosentan metabolite Ro 47-8634Details
Bosentan metabolite Ro 48-5033
Not Available
Bosentan metabolite Ro 64-1056Details
Bosentan metabolite Ro 47-8634
Not Available
Bosentan metabolite Ro 64-1056Details
Route of eliminationBosentan is eliminated by biliary excretion following metabolism in the liver.
Half lifeTerminal elimination half-life is about 5 hours in healthy adult subjects.
Clearance
  • 4 L/h [patients with pulmonary arterial hypertension]
ToxicityBosentan has been given as a single dose of up to 2400 mg in normal volunteers, or up to 2000 mg/day for 2 months in patients, without any major clinical consequences. The most common side effect was headache of mild to moderate intensity. In the cyclosporine A interaction study, in which doses of 500 and 1000 mg b.i.d. of bosentan were given concomitantly with cyclosporine A, trough plasma concentrations of bosentan increased 30-fold, resulting in severe headache, nausea, and vomiting, but no serious adverse events. Mild decreases in blood pressure and increases in heart rate were observed. There is no specific experience of overdosage with bosentan beyond the doses described above. Massive overdosage may result in pronounced hypotension requiring active cardiovascular support.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9253
Blood Brain Barrier-0.7419
Caco-2 permeable-0.8956
P-glycoprotein substrateNon-substrate0.5738
P-glycoprotein inhibitor INon-inhibitor0.6175
P-glycoprotein inhibitor IINon-inhibitor0.5092
Renal organic cation transporterNon-inhibitor0.9149
CYP450 2C9 substrateNon-substrate0.5926
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5132
CYP450 1A2 substrateNon-inhibitor0.7203
CYP450 2C9 inhibitorInhibitor0.518
CYP450 2D6 inhibitorNon-inhibitor0.8755
CYP450 2C19 inhibitorNon-inhibitor0.5219
CYP450 3A4 inhibitorInhibitor0.8407
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.772
Ames testNon AMES toxic0.6147
CarcinogenicityNon-carcinogens0.6515
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2676 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9679
hERG inhibition (predictor II)Non-inhibitor0.572
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actelion ltd
Packagers
Dosage forms
FormRouteStrength
Tabletoral125.0 mg
Tabletoral125 mg
Tabletoral62.5 mg
Tablet, film coatedoral125 mg/1
Tablet, film coatedoral62.5 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2071193 No1998-08-252012-06-12Canada
US5292740 No1995-11-202015-11-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityPoorly soluble in water (1.0 mg/100 ml) and in aqueous solutions at low pH (0.1 mg/100 ml at pH 1.1 and 4.0; 0.2 mg/100 ml at pH 5.0). Solubility increases at higher pH values (43 mg/100 ml at pH 7.5).Not Available
logP3.7Not Available
Caco2 permeability-5.98ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00904 mg/mLALOGPS
logP4.18ALOGPS
logP4.94ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)5.8ChemAxon
pKa (Strongest Basic)-0.43ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area145.65 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity166.66 m3·mol-1ChemAxon
Polarizability57.89 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Maurizio TADDEI, Diletta Naldini, Pietro Allegrini, Gabriele Razzetti, Simone Mantegazza, “Process for the Preparation of Bosentan.” U.S. Patent US20090156811, issued June 18, 2009.

US20090156811
General ReferencesNot Available
External Links
ATC CodesC02KX01
AHFS Codes
  • 24:12.92
PDB EntriesNot Available
FDA labelDownload (424 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Bosentan.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Bosentan.
AbirateroneThe serum concentration of Bosentan can be increased when it is combined with Abiraterone.
AcebutololBosentan may increase the hypotensive activities of Acebutolol.
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Bosentan.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Bosentan.
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Bosentan.
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Bosentan.
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Bosentan.
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Bosentan.
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Bosentan.
AlfuzosinAlfuzosin may increase the hypotensive activities of Bosentan.
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Bosentan.
AliskirenAliskiren may increase the hypotensive activities of Bosentan.
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Bosentan.
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Bosentan.
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Bosentan.
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Bosentan.
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Bosentan.
AlprenololBosentan may increase the hypotensive activities of Alprenolol.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Bosentan.
AmbrisentanAmbrisentan may increase the hypotensive activities of Bosentan.
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Bosentan.
AmifostineBosentan may increase the hypotensive activities of Amifostine.
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Bosentan.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Bosentan.
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Bosentan.
AmiodaroneThe serum concentration of Bosentan can be increased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Bosentan.
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Bosentan.
AmlodipineAmlodipine may increase the hypotensive activities of Bosentan.
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Bosentan.
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Bosentan.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Bosentan.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Bosentan.
AprepitantThe serum concentration of Bosentan can be increased when it is combined with Aprepitant.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Bosentan.
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Bosentan.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Bosentan.
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Bosentan.
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Bosentan.
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Bosentan.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Bosentan.
AtazanavirThe serum concentration of Bosentan can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Bosentan.
AtomoxetineThe serum concentration of Bosentan can be increased when it is combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Bosentan.
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Bosentan.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Bosentan.
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Bosentan.
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Bosentan.
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Bosentan.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Bosentan.
BenazeprilBenazepril may increase the hypotensive activities of Bosentan.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bosentan.
BenmoxinBenmoxin may increase the hypotensive activities of Bosentan.
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Bosentan.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Bosentan.
BepridilBosentan may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Bosentan.
BethanidineBethanidine may increase the hypotensive activities of Bosentan.
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Bosentan.
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Bosentan.
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Bosentan.
BimatoprostBosentan may increase the hypotensive activities of Bimatoprost.
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Bosentan.
BisoprololBisoprolol may increase the hypotensive activities of Bosentan.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Bosentan.
BoceprevirThe serum concentration of Bosentan can be increased when it is combined with Boceprevir.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Bosentan.
BortezomibThe serum concentration of Bosentan can be increased when it is combined with Bortezomib.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Bosentan.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Bosentan.
BretyliumBosentan may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Bosentan.
BrimonidineBosentan may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Bosentan.
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Bosentan.
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Bosentan.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Bosentan.
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Bosentan.
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Bosentan.
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Bosentan.
BupranololBosentan may increase the hypotensive activities of Bupranolol.
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Bosentan.
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Bosentan.
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Bosentan.
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Bosentan.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Bosentan.
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Bosentan.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Bosentan.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Bosentan.
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Bosentan.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Bosentan.
CandesartanBosentan may increase the hypotensive activities of Candesartan.
CandoxatrilBosentan may increase the hypotensive activities of Candoxatril.
CapecitabineThe serum concentration of Bosentan can be increased when it is combined with Capecitabine.
CaptoprilBosentan may increase the hypotensive activities of Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Bosentan.
CarbamazepineThe metabolism of Bosentan can be increased when combined with Carbamazepine.
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Bosentan.
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Bosentan.
CaroxazoneCaroxazone may increase the hypotensive activities of Bosentan.
CarteololCarteolol may increase the hypotensive activities of Bosentan.
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Bosentan.
CarvedilolCarvedilol may increase the hypotensive activities of Bosentan.
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Bosentan.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Bosentan.
CeliprololCeliprolol may increase the hypotensive activities of Bosentan.
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Bosentan.
CeritinibThe serum concentration of Bosentan can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Bosentan.
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Bosentan.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Bosentan.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Bosentan.
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Bosentan.
ChlorothiazideBosentan may increase the hypotensive activities of Chlorothiazide.
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Bosentan.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Bosentan.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bosentan.
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Bosentan.
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Bosentan.
CholecalciferolThe serum concentration of Bosentan can be increased when it is combined with Cholecalciferol.
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Bosentan.
CilazaprilBosentan may increase the hypotensive activities of Cilazapril.
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Bosentan.
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Bosentan.
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Bosentan.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Bosentan.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Bosentan.
ClarithromycinThe serum concentration of Bosentan can be increased when it is combined with Clarithromycin.
ClemastineThe serum concentration of Bosentan can be increased when it is combined with Clemastine.
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Bosentan.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Bosentan.
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Bosentan.
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Bosentan.
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Bosentan.
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Bosentan.
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Bosentan.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Bosentan.
ClonidineClonidine may increase the hypotensive activities of Bosentan.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Bosentan.
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Bosentan.
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Bosentan.
ClotrimazoleThe serum concentration of Bosentan can be increased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Bosentan.
CobicistatThe serum concentration of Bosentan can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Bosentan.
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Bosentan.
CodeineThe serum concentration of Codeine can be decreased when it is combined with Bosentan.
Coenzyme Q10The metabolism of Coenzyme Q10 can be increased when combined with Bosentan.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Bosentan.
ConivaptanThe serum concentration of Bosentan can be increased when it is combined with Conivaptan.
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Bosentan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Bosentan.
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Bosentan.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Bosentan.
CrizotinibThe serum concentration of Bosentan can be increased when it is combined with Crizotinib.
CryptenamineBosentan may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Bosentan.
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Bosentan.
CyclosporineThe serum concentration of Bosentan can be increased when it is combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Bosentan.
CyclothiazideBosentan may increase the hypotensive activities of Cyclothiazide.
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Bosentan.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Bosentan.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Bosentan.
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Bosentan.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Bosentan.
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Bosentan.
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Bosentan.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Bosentan.
DarunavirThe serum concentration of Bosentan can be increased when it is combined with Darunavir.
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Bosentan.
DasatinibThe serum concentration of Bosentan can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Bosentan.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Bosentan.
DebrisoquinBosentan may increase the hypotensive activities of Debrisoquin.
DeferasiroxThe serum concentration of Bosentan can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be decreased when it is combined with Bosentan.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Bosentan.
DelavirdineThe serum concentration of Bosentan can be increased when it is combined with Delavirdine.
DeserpidineBosentan may increase the hypotensive activities of Deserpidine.
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Bosentan.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Bosentan.
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Bosentan.
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Bosentan.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Bosentan.
DiazoxideDiazoxide may increase the hypotensive activities of Bosentan.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Bosentan.
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Bosentan.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Bosentan.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Bosentan.
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Bosentan.
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Bosentan.
DihydroergotamineThe serum concentration of Bosentan can be increased when it is combined with Dihydroergotamine.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Bosentan.
DiltiazemThe serum concentration of Bosentan can be increased when it is combined with Diltiazem.
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Bosentan.
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Bosentan.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Bosentan.
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Bosentan.
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Bosentan.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Bosentan.
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Bosentan.
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Bosentan.
DorzolamideDorzolamide may increase the hypotensive activities of Bosentan.
DoxazosinBosentan may increase the hypotensive activities of Doxazosin.
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Bosentan.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Bosentan.
DoxycyclineThe serum concentration of Bosentan can be increased when it is combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Bosentan.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Bosentan.
DronedaroneThe serum concentration of Bosentan can be increased when it is combined with Dronedarone.
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Bosentan.
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Bosentan.
EfavirenzThe serum concentration of Bosentan can be increased when it is combined with Efavirenz.
EfonidipineBosentan may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Bosentan.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Bosentan.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Bosentan.
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Bosentan.
EnalaprilEnalapril may increase the hypotensive activities of Bosentan.
EnalaprilatBosentan may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Bosentan.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Bosentan.
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Bosentan.
EpoprostenolBosentan may increase the hypotensive activities of Epoprostenol.
EprosartanBosentan may increase the hypotensive activities of Eprosartan.
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Bosentan.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Bosentan.
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Bosentan.
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Bosentan.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Bosentan.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Bosentan.
ErythromycinThe serum concentration of Bosentan can be increased when it is combined with Erythromycin.
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Bosentan.
Eslicarbazepine acetateThe serum concentration of Bosentan can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Bosentan.
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Bosentan.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Bosentan.
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Bosentan.
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Bosentan.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Bosentan.
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Bosentan.
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Bosentan.
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Bosentan.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bosentan.
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Bosentan.
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Bosentan.
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Bosentan.
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Bosentan.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Bosentan.
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Bosentan.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Bosentan.
EtravirineThe serum concentration of Bosentan can be increased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Bosentan.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Bosentan.
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Bosentan.
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Bosentan.
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Bosentan.
FelodipineFelodipine may increase the hypotensive activities of Bosentan.
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Bosentan.
FenoldopamBosentan may increase the hypotensive activities of Fenoldopam.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Bosentan.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Bosentan.
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Bosentan.
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Bosentan.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Bosentan.
FloxuridineThe serum concentration of Bosentan can be increased when it is combined with Floxuridine.
FluconazoleThe serum concentration of Bosentan can be increased when it is combined with Fluconazole.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Bosentan.
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Bosentan.
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Bosentan.
FluorouracilThe serum concentration of Bosentan can be increased when it is combined with Fluorouracil.
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Bosentan.
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Bosentan.
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Bosentan.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Bosentan.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Bosentan.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Bosentan.
FluvastatinThe serum concentration of Bosentan can be increased when it is combined with Fluvastatin.
FluvoxamineThe serum concentration of Bosentan can be increased when it is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Bosentan.
FosamprenavirThe serum concentration of Bosentan can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Bosentan can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Bosentan.
FosphenytoinThe metabolism of Bosentan can be increased when combined with Fosphenytoin.
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Bosentan.
FurazolidoneFurazolidone may increase the hypotensive activities of Bosentan.
Fusidic AcidThe serum concentration of Bosentan can be increased when it is combined with Fusidic Acid.
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Bosentan.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Bosentan.
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Bosentan.
GemfibrozilThe serum concentration of Bosentan can be increased when it is combined with Gemfibrozil.
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Bosentan.
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Bosentan.
GlyburideGlyburide may increase the hepatotoxic activities of Bosentan.
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Bosentan.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Bosentan.
GuanabenzBosentan may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Bosentan.
GuanethidineBosentan may increase the hypotensive activities of Guanethidine.
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Bosentan.
GuanfacineGuanfacine may increase the hypotensive activities of Bosentan.
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Bosentan.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Bosentan.
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Bosentan.
HexamethoniumBosentan may increase the hypotensive activities of Hexamethonium.
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Bosentan.
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Bosentan.
HydracarbazineHydracarbazine may increase the hypotensive activities of Bosentan.
HydralazineBosentan may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideBosentan may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Bosentan.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Bosentan.
HydroflumethiazideBosentan may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Bosentan.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Bosentan.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Bosentan.
IdelalisibThe serum concentration of Bosentan can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of Ifosfamide can be decreased when it is combined with Bosentan.
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Bosentan.
IloprostIloprost may increase the hypotensive activities of Bosentan.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Bosentan.
ImatinibThe serum concentration of Bosentan can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Bosentan.
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Bosentan.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Bosentan.
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Bosentan.
IndapamideIndapamide may increase the hypotensive activities of Bosentan.
IndenololBosentan may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Bosentan.
IndinavirThe serum concentration of Bosentan can be increased when it is combined with Indinavir.
IndoraminBosentan may increase the hypotensive activities of Indoramin.
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Bosentan.
IproclozideIproclozide may increase the hypotensive activities of Bosentan.
IproniazidIproniazid may increase the hypotensive activities of Bosentan.
IrbesartanThe serum concentration of Bosentan can be increased when it is combined with Irbesartan.
IrbesartanBosentan may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Bosentan.
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Bosentan.
IsavuconazoniumThe serum concentration of Bosentan can be increased when it is combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bosentan.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Bosentan.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Bosentan.
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Bosentan.
IsradipineThe serum concentration of Bosentan can be increased when it is combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Bosentan.
ItraconazoleThe serum concentration of Bosentan can be increased when it is combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Bosentan.
IvacaftorThe serum concentration of Bosentan can be increased when it is combined with Ivacaftor.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Bosentan.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Bosentan.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Bosentan.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Bosentan.
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Bosentan.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Bosentan.
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Bosentan.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Bosentan.
KetoconazoleThe serum concentration of Bosentan can be increased when it is combined with Ketoconazole.
LabetalolBosentan may increase the hypotensive activities of Labetalol.
LacidipineBosentan may increase the hypotensive activities of Lacidipine.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Bosentan.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Bosentan.
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Bosentan.
LatanoprostBosentan may increase the hypotensive activities of Latanoprost.
LeflunomideThe serum concentration of Bosentan can be increased when it is combined with Leflunomide.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Bosentan.
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Bosentan.
LercanidipineLercanidipine may increase the hypotensive activities of Bosentan.
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Bosentan.
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Bosentan.
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Bosentan.
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Bosentan.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Bosentan.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Bosentan.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Bosentan.
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Bosentan.
LisinoprilBosentan may increase the hypotensive activities of Lisinopril.
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Bosentan.
LofexidineBosentan may increase the hypotensive activities of Lofexidine.
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Bosentan.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Bosentan.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Bosentan.
LopinavirThe serum concentration of Bosentan can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Bosentan.
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Bosentan.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Bosentan.
LosartanThe serum concentration of Bosentan can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Bosentan.
LovastatinThe serum concentration of Bosentan can be increased when it is combined with Lovastatin.
LuliconazoleThe serum concentration of Bosentan can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Bosentan can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Bosentan.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Bosentan.
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Bosentan.
MacitentanMacitentan may increase the hypotensive activities of Bosentan.
ManidipineBosentan may increase the hypotensive activities of Manidipine.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Bosentan.
MebanazineMebanazine may increase the hypotensive activities of Bosentan.
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Bosentan.
MecamylamineBosentan may increase the hypotensive activities of Mecamylamine.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Bosentan.
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Bosentan.
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Bosentan.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Bosentan.
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Bosentan.
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Bosentan.
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Bosentan.
MethyldopaBosentan may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Bosentan.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bosentan.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Bosentan.
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Bosentan.
MetipranololBosentan may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Bosentan.
MetoprololMetoprolol may increase the hypotensive activities of Bosentan.
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Bosentan.
MevastatinThe metabolism of Mevastatin can be increased when combined with Bosentan.
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Bosentan.
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Bosentan.
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Bosentan.
MibefradilMibefradil may increase the hypotensive activities of Bosentan.
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Bosentan.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Bosentan.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Bosentan.
MifepristoneThe serum concentration of Bosentan can be increased when it is combined with Mifepristone.
MinaprineMinaprine may increase the hypotensive activities of Bosentan.
MinoxidilMinoxidil may increase the hypotensive activities of Bosentan.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Bosentan.
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Bosentan.
MitotaneThe serum concentration of Bosentan can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the hypotensive activities of Bosentan.
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Bosentan.
MoexiprilBosentan may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Bosentan.
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Bosentan.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Bosentan.
MoxonidineBosentan may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Bosentan.
NadololBosentan may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Bosentan can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Bosentan.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Bosentan.
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Bosentan.
NebivololBosentan may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Bosentan.
NefazodoneThe serum concentration of Bosentan can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Bosentan.
NelfinavirThe serum concentration of Bosentan can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Bosentan can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Bosentan.
NevirapineThe serum concentration of Bosentan can be increased when it is combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Bosentan.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Bosentan.
NicardipineThe serum concentration of Bosentan can be increased when it is combined with Nicardipine.
NicorandilBosentan may increase the hypotensive activities of Nicorandil.
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Bosentan.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Bosentan.
NiguldipineBosentan may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Bosentan.
NilotinibThe serum concentration of Bosentan can be increased when it is combined with Nilotinib.
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Bosentan.
NilvadipineNilvadipine may increase the hypotensive activities of Bosentan.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Bosentan.
NimodipineNimodipine may increase the hypotensive activities of Bosentan.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Bosentan.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Bosentan.
NisoldipineNisoldipine may increase the hypotensive activities of Bosentan.
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Bosentan.
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Bosentan.
NitrendipineNitrendipine may increase the hypotensive activities of Bosentan.
NitroprussideNitroprusside may increase the hypotensive activities of Bosentan.
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Bosentan.
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Bosentan.
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Bosentan.
ObinutuzumabBosentan may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Bosentan.
OlaparibThe serum concentration of Bosentan can be increased when it is combined with Olaparib.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Bosentan.
OlmesartanOlmesartan may increase the hypotensive activities of Bosentan.
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Bosentan.
OmapatrilatBosentan may increase the hypotensive activities of Omapatrilat.
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Bosentan.
OmeprazoleThe serum concentration of Bosentan can be increased when it is combined with Omeprazole.
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Bosentan.
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Bosentan.
OsimertinibThe serum concentration of Bosentan can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Bosentan.
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Bosentan.
OxprenololBosentan may increase the hypotensive activities of Oxprenolol.
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Bosentan.
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Bosentan.
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Bosentan.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Bosentan.
PalbociclibThe serum concentration of Bosentan can be increased when it is combined with Palbociclib.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Bosentan.
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Bosentan.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Bosentan.
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Bosentan.
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Bosentan.
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Bosentan.
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Bosentan.
PargylineBosentan may increase the hypotensive activities of Pargyline.
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Bosentan.
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Bosentan.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Bosentan.
PenbutololBosentan may increase the hypotensive activities of Penbutolol.
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Bosentan.
PentobarbitalThe metabolism of Bosentan can be increased when combined with Pentobarbital.
PentoliniumBosentan may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bosentan.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Bosentan.
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Bosentan.
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Bosentan.
PerindoprilBosentan may increase the hypotensive activities of Perindopril.
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Bosentan.
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Bosentan.
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Bosentan.
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Bosentan.
PhenelzinePhenelzine may increase the hypotensive activities of Bosentan.
PhenindioneThe metabolism of Phenindione can be increased when combined with Bosentan.
PheniprazinePheniprazine may increase the hypotensive activities of Bosentan.
PhenobarbitalThe metabolism of Bosentan can be increased when combined with Phenobarbital.
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Bosentan.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Bosentan.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bosentan.
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Bosentan.
PhentolamineBosentan may increase the hypotensive activities of Phentolamine.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Bosentan.
PhenytoinThe metabolism of Bosentan can be increased when combined with Phenytoin.
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Bosentan.
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Bosentan.
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Bosentan.
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Bosentan.
PinacidilPinacidil may increase the hypotensive activities of Bosentan.
PindololBosentan may increase the hypotensive activities of Pindolol.
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Bosentan.
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Bosentan.
PirlindolePirlindole may increase the hypotensive activities of Bosentan.
PitavastatinThe metabolism of Pitavastatin can be increased when combined with Bosentan.
PivhydrazinePivhydrazine may increase the hypotensive activities of Bosentan.
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Bosentan.
PolythiazideBosentan may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Bosentan.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Bosentan.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Bosentan.
PosaconazoleThe serum concentration of Bosentan can be increased when it is combined with Posaconazole.
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Bosentan.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Bosentan.
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Bosentan.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Bosentan.
PrazosinPrazosin may increase the hypotensive activities of Bosentan.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Bosentan.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Bosentan.
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Bosentan.
PrimidoneThe metabolism of Bosentan can be increased when combined with Primidone.
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Bosentan.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Bosentan.
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Bosentan.
PromazineThe serum concentration of Promazine can be decreased when it is combined with Bosentan.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Bosentan.
PropofolThe serum concentration of Propofol can be decreased when it is combined with Bosentan.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Bosentan.
PropranololPropranolol may increase the hypotensive activities of Bosentan.
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Bosentan.
PyrimethamineThe serum concentration of Bosentan can be increased when it is combined with Pyrimethamine.
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Bosentan.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Bosentan.
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Bosentan.
QuinaprilBosentan may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Bosentan.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Bosentan.
QuinineThe serum concentration of Bosentan can be increased when it is combined with Quinine.
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Bosentan.
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Bosentan.
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Bosentan.
RamiprilRamipril may increase the hypotensive activities of Bosentan.
RanolazineThe serum concentration of Bosentan can be increased when it is combined with Ranolazine.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Bosentan.
RasagilineRasagiline may increase the hypotensive activities of Bosentan.
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Bosentan.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Bosentan.
RemikirenRemikiren may increase the hypotensive activities of Bosentan.
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Bosentan.
RescinnamineBosentan may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Bosentan.
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Bosentan.
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Bosentan.
RifabutinThe metabolism of Bosentan can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Bosentan.
RifapentineThe metabolism of Bosentan can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Bosentan.
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Bosentan.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Bosentan.
RiociguatRiociguat may increase the hypotensive activities of Bosentan.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Bosentan.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Bosentan.
RitonavirThe serum concentration of Bosentan can be increased when it is combined with Ritonavir.
RituximabBosentan may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Bosentan.
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Bosentan.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Bosentan.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Bosentan.
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Bosentan.
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Bosentan.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Bosentan.
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Bosentan.
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Bosentan.
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Bosentan.
SafrazineSafrazine may increase the hypotensive activities of Bosentan.
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Bosentan.
SaprisartanBosentan may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Bosentan.
SaquinavirThe serum concentration of Bosentan can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Bosentan.
SecobarbitalThe metabolism of Bosentan can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Bosentan.
SelegilineSelegiline may increase the hypotensive activities of Bosentan.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Bosentan.
SelexipagSelexipag may increase the hypotensive activities of Bosentan.
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Bosentan.
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Bosentan.
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Bosentan.
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Bosentan.
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Bosentan.
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Bosentan.
SildenafilThe serum concentration of Bosentan can be increased when it is combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Bosentan.
SiltuximabThe serum concentration of Bosentan can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Bosentan can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Bosentan.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Bosentan.
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Bosentan.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Bosentan.
SitaxentanBosentan may increase the hypotensive activities of Sitaxentan.
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Bosentan.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Bosentan.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Bosentan.
SorafenibThe serum concentration of Bosentan can be increased when it is combined with Sorafenib.
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Bosentan.
SpiraprilBosentan may increase the hypotensive activities of Spirapril.
St. John's WortThe serum concentration of Bosentan can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Bosentan can be increased when it is combined with Stiripentol.
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Bosentan.
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Bosentan.
SulfadiazineThe serum concentration of Bosentan can be increased when it is combined with Sulfadiazine.
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Bosentan.
SulfamethoxazoleThe serum concentration of Bosentan can be increased when it is combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Bosentan.
SulfisoxazoleThe serum concentration of Bosentan can be increased when it is combined with Sulfisoxazole.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Bosentan.
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Bosentan.
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Bosentan.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Bosentan.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Bosentan.
TadalafilTadalafil may increase the antihypertensive activities of Bosentan.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Bosentan.
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Bosentan.
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Bosentan.
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Bosentan.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Bosentan.
TelaprevirThe serum concentration of Bosentan can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Bosentan.
TelithromycinThe serum concentration of Bosentan can be increased when it is combined with Telithromycin.
TelmisartanBosentan may increase the hypotensive activities of Telmisartan.
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Bosentan.
TemocaprilBosentan may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Bosentan.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Bosentan.
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Bosentan.
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Bosentan.
TerlipressinBosentan may increase the hypotensive activities of Terlipressin.
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Bosentan.
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Bosentan.
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Bosentan.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Bosentan.
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Bosentan.
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Bosentan.
TiboloneBosentan may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Bosentan.
TicagrelorThe serum concentration of Bosentan can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Bosentan.
TiclopidineThe serum concentration of Bosentan can be increased when it is combined with Ticlopidine.
TicrynafenBosentan may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Bosentan.
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Bosentan.
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Bosentan.
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Bosentan.
TocilizumabThe serum concentration of Bosentan can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Bosentan.
TolazolineBosentan may increase the hypotensive activities of Tolazoline.
TolbutamideThe serum concentration of Bosentan can be increased when it is combined with Tolbutamide.
ToloxatoneToloxatone may increase the hypotensive activities of Bosentan.
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Bosentan.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Bosentan.
TorasemideTorasemide may increase the hypotensive activities of Bosentan.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Bosentan.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Bosentan.
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Bosentan.
TrandolaprilTrandolapril may increase the hypotensive activities of Bosentan.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bosentan.
TranylcypromineTranylcypromine may increase the hypotensive activities of Bosentan.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Bosentan.
TravoprostTravoprost may increase the hypotensive activities of Bosentan.
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Bosentan.
TreprostinilTreprostinil may increase the hypotensive activities of Bosentan.
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Bosentan.
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Bosentan.
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Bosentan.
TrichlormethiazideBosentan may increase the hypotensive activities of Trichlormethiazide.
TrimazosinBosentan may increase the hypotensive activities of Trimazosin.
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Bosentan.
TrimethaphanBosentan may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Bosentan.
TrimethoprimThe serum concentration of Bosentan can be increased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Bosentan.
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Bosentan.
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Bosentan.
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Bosentan.
UdenafilUdenafil may increase the antihypertensive activities of Bosentan.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Bosentan.
UnoprostoneBosentan may increase the hypotensive activities of Unoprostone.
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Bosentan.
Valproic AcidThe serum concentration of Bosentan can be increased when it is combined with Valproic Acid.
ValsartanThe serum concentration of Bosentan can be increased when it is combined with Valsartan.
ValsartanBosentan may increase the hypotensive activities of Valsartan.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Bosentan.
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Bosentan.
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Bosentan.
VardenafilVardenafil may increase the antihypertensive activities of Bosentan.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Bosentan.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Bosentan.
VenlafaxineThe serum concentration of Bosentan can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Bosentan.
VerapamilThe serum concentration of Bosentan can be increased when it is combined with Verapamil.
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Bosentan.
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Bosentan.
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Bosentan.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Bosentan.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Bosentan.
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Bosentan.
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Bosentan.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Bosentan.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Bosentan.
VoriconazoleThe serum concentration of Bosentan can be increased when it is combined with Voriconazole.
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Bosentan.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Bosentan.
XylometazolineBosentan may increase the hypotensive activities of Xylometazoline.
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Bosentan.
YohimbineYohimbine may decrease the antihypertensive activities of Bosentan.
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Bosentan.
ZafirlukastThe serum concentration of Bosentan can be increased when it is combined with Zafirlukast.
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Bosentan.
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Bosentan.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Bosentan.
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Bosentan.
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Bosentan.
ZiprasidoneThe serum concentration of Bosentan can be increased when it is combined with Ziprasidone.
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Bosentan.
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Bosentan.
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Bosentan.
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Bosentan.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Peptide hormone binding
Specific Function:
Non-specific receptor for endothelin 1, 2, and 3. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
EDNRB
Uniprot ID:
P24530
Molecular Weight:
49643.255 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Gardiner SM, Kemp PA, March JE, Bennett T: Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats. Br J Pharmacol. 1994 Jul;112(3):823-30. [PubMed:7921608 ]
  3. Gupta SK, Saxena A, Singh U, Arya DS: Bosentan, the mixed ETA-ETB endothelin receptor antagonist, attenuated oxidative stress after experimental myocardial ischemia and reperfusion. Mol Cell Biochem. 2005 Jul;275(1-2):67-74. [PubMed:16335785 ]
  4. Marano G, Palazzesi S, Bernucci P, Grigioni M, Formigari R, Ballerini L: ET(A)/ET(B) receptor antagonist bosentan inhibits neointimal development in collared carotid arteries of rabbits. Life Sci. 1998;63(18):PL259-66. [PubMed:9806221 ]
  5. Richard V, Kaeffer N, Hogie M, Tron C, Blanc T, Thuillez C: Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist. Br J Pharmacol. 1994 Nov;113(3):869-76. [PubMed:7858879 ]
  6. Said SA, Ammar el SM, Suddek GM: Effect of bosentan (ETA/ETB receptor antagonist) on metabolic changes during stress and diabetes. Pharmacol Res. 2005 Feb;51(2):107-15. [PubMed:15629255 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3.
Gene Name:
EDNRA
Uniprot ID:
P25101
Molecular Weight:
48721.76 Da
References
  1. Albertini M, Lafortuna CL, Ciminaghi B, Mazzola S, Clement MG: Endothelin involvement in respiratory centre activity. Prostaglandins Leukot Essent Fatty Acids. 2001 Sep;65(3):157-63. [PubMed:11728166 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Kiowski W, Sutsch G, Oechslin E, Bertel O: Hemodynamic effects of bosentan in patients with chronic heart failure. Heart Fail Rev. 2001 Dec;6(4):325-34. [PubMed:11447307 ]
  4. Kramp R, Fourmanoir P, Caron N: Endothelin resets renal blood flow autoregulatory efficiency during acute blockade of NO in the rat. Am J Physiol Renal Physiol. 2001 Dec;281(6):F1132-40. [PubMed:11704565 ]
  5. Martin C, Held HD, Uhlig S: Differential effects of the mixed ET(A)/ET(B)-receptor antagonist bosentan on endothelin-induced bronchoconstriction, vasoconstriction and prostacyclin release. Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):128-36. [PubMed:10961375 ]
  6. Sihvola RK, Pulkkinen VP, Koskinen PK, Lemstrom KB: Crosstalk of endothelin-1 and platelet-derived growth factor in cardiac allograft arteriosclerosis. J Am Coll Cardiol. 2002 Feb 20;39(4):710-7. [PubMed:11849873 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Dingemanse J, Schaarschmidt D, van Giersbergen PL: Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet. 2003;42(3):293-301. [PubMed:12603176 ]
  2. Dingemanse J, van Giersbergen PL: Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004;43(15):1089-115. [PubMed:15568889 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ: The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001 Apr;69(4):223-31. [PubMed:11309550 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 31, 2016 02:13